Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Therapeutic
- Pharmaceuticals
- Disease
- Diabetes Treatment
- obesity
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2776
License Grant
In fiscal 2006, the Licensee issued 414,492 common shares to the Canadian Licensor in exchange for patents related to the use of GLP-1 in type I diabetes patients.
License Property
Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of gastric emptying. We examined the potential of GLP-1 to improve glycemic control in type 1 diabetes with no endogenous insulin secretion.
Field of Use
The Licensee product is TT401, a dual agonist of the GLP-1 (Glucagon-Like Peptide-1) and glucagon receptors. These receptors play an integral role in regulating appetite, food intake, satiety and energy utilization in the body. Stimulating both these receptors, TT401 has the potential to regulate blood glucose levels with important additional outcomes, such as weight loss.
IPSCIO Record ID: 340300
License Grant
This agreement is in respect to a research and collaboration for the development of Glucagon & GLP-1 Dual Agonists between the Licensee and the Denmark Licensor.
License Property
Glucagon & GLP-1 Dual Agonists is part of the portfolio that includes ZP 7570, a potential once-weekly GLP-1-GLP-2 agonist for treatment of SBS in phase 2 development.
Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It works to raise the concentration of glucose and fatty acids in the bloodstream, and is considered to be the main catabolic hormone of the body.[3] It is also used as a medication to treat a number of health conditions. GLP-1 and GLP-2 are identifiers. Glucagon binds to the glucagon receptor, a G protein-coupled receptor, located in the plasma membrane of the cell.
Field of Use
Field of use is for the treatment of SBS (short bowel syndrome).
SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function.
IPSCIO Record ID: 211839
License Grant
The Australian Licensee desires to collaborate with an Australian University for a Project using the Research Expertise and a license of all Intellectual Property in the result of the Project.
License Property
The University has expertise in one or more areas of the Research Fields, and owns or has an exclusive license of the Pre-existing Intellectual Property. The Patent has been licensed exclusively to the University and is for the Treatment of Obesity. Products means the products and results of the Project.
Australian Provisional Patent Application No. PO 1085/96 (annexed hereto) entitled “Treatment of Obesity†filed on 18 July 1996.
Field of Use
The primary aim of this research program is to discover novel genes that will be integral to the development of new therapeutic approaches directed at the treatment and prevention of obesity.
The Project means scientific research using the Research Expertise into the role of potential pharmaceutical agents on food intake, body weight control and parameters of insulin resistance and diabetes as examined in studies into therapeutic regulators of food intake and appetite.
IPSCIO Record ID: 182111
License Grant
The Company entered into a MLA to license the rights to Licensor programs.
License Property
This program is for a FBPase Inhibitor. Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
FBPase inhibitor program is for type 2 diabetes, a Selective Androgen Receptor Modulator (SARM) program for muscle wasting, a Thyroid Hormone Receptor-ß (TRß) Agonist program for dyslipidemia, an Erythropoietin Receptor (EPOR) Agonist program for anemia, and an Enterocyte-Directed Diacylglycerol Acyltransferase-1 (DGAT-1) Inhibitor program for dyslipidemia.
FBPase is an enzyme that plays an important role in endogenous glucose production, or the synthesis of glucose by the body.
Field of Use
This agreement is for the drug industry.
IPSCIO Record ID: 214173
License Grant
Pursuant to this agreement, the Australian Licensor, a non-profit organization, the owner of a Sand Rat colony based at an Australian University, and has agreed to make the Sand Rats available to the University for the purposes of the Project.
The Australian Licensee desires to collaborate with the Australian University for the Project using the Research Expertise and a license of all Intellectual Property in the result of the Project.
License Property
The license is for use of the Sand Rat colony for the project.
The Israeli Sand Rat is the only animal model which develops a broad spectrum of defects in food intake, body fat and diabetes comparable to similar defects measured in humans. For example, it is possible in the Israeli Sand rat to find 2 offspring from the same parents, one will remain lean and free from diabetes, while the other overeats and subsequently develops obesity. Both of these animals have exactly the same environmental influences – Why does one overeat.
By utilising the latest techniques available in molecular biology (gene fingerprinting) we will be able to determine the different genes being expressed in obese animals – isolate these genes and determine their role in obesity development. Novel genes uncovered will be patented and their metabolic potential determined.
Field of Use
The primary aim of this research program is to discover novel genes that will be integral to the development of new therapeutic approaches directed at the treatment and prevention of obesity.
The Project means scientific research using the Research Expertise into the role of potential pharmaceutical agents on food intake, body weight control and parameters of insulin resistance and diabetes as examined in studies into therapeutic regulators of food intake and appetite.
IPSCIO Record ID: 6157
License Grant
The Licensee entered into a licensing agreement with a former shareholder for the commercialization of either of the VPAC2 analogs for any purpose.
License Property
Diabetes – VPAC2 agonists exert their effects through a separate receptor pathway than incretinin mimetic drugs like GLP-1 agonists ((i)Byetta®), and DPP-IV inhibitors ((ii)Januvia®). By targeting selective VPAC2 receptors, the FM-TP2000 series of analogs are designed to mimic the natural, neuronal signal, rather than the hormonal one, to stimulate beta cells to release insulin in a glucose-dependent fashion. This provides an alternative therapeutic approach, which could achieve benefits similar to Byetta, but may also be complementary in effect.
Inflammatory Lung Disease – VPAC2 agonists have bronchodilating, and anti-inflammatory effects. By targeting VPAC2 receptors, the FM-TP3000 series of compounds are designed to suppress the release of inflammatory mediators (TNF-alpha, IL-12), as well as suppressing the eosinophil response to stimuli. This provides an alternate therapeutic approach to treating asthma, chronic obstructive pulmonary disease (COPD), and Pulmonary Arterial Hypertension (PAH).
Field of Use
The rights granted apply to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
